Servier eyes up Ideaya’s darovasertib
As pivotal data approach, the French group pays $210m for ex-US rights.
MacroGenics faces new competition
Duality takes its Adam9-targeting conjugate into the clinic.
The month ahead: September’s upcoming events
It’s a new term for biotech and its investors.
Colorectal cancer is next for VEGF bispecifics
Pumitamig is the latest to be tested in first-line disease.
Ivonescimab back in tune
China's Harmoni-A trial hits on overall survival, but hopes for a global phase 3 seem optimistic.
A new multiple myeloma race heats up
Qilu moves its GPRC5D T-cell engager into phase 3, but trispecifics set the new pace.
A new myeloid cell engager enters the clinic
After Dren secured buy-in from Novartis, LTZ becomes a clinical player.
BeOne cashes in its Imdelltra royalty
Meanwhile, Royalty Pharma stakes $885m on $2.8bn sales by 2035.
FDA doubles down on overall survival
New draft guidance could see the agency getting ever stricter.
A mystery Moderna asset hits the clinic
mRNA-2808 could be a multispecific mRNA-encoded T-cell engager therapy.
